Advertisement
Screener

Cartesian Therapeutics, Inc. (RNAC) Graph

RNAC Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $20.43M; Operating expenses $29.16M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $19.46M; Operating expenses $26.58M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $14.69M*; Operating expenses $79.59M*; Income tax (m).
  • 2025-09-30: Revenue (m); Research and development $13.80M; Operating expenses $21.52M; Income tax (m).

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

RNAC revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Operating Segment$0.00Revenue$0.00Operating expenses$29.16MOperating income-$29.16MOther income, net$126.00KResearch & development$20.43MNet income$15.77M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$20.43M$29.16M(m)$15.77M
2026-03-31(m)$19.46M$26.58M(m)-$39.18M
2025-12-31(m)$14.69M*$79.59M*(m)-$92.58M*
2025-09-30(m)$13.80M$21.52M(m)-$35.90M
2025-06-30(m)$14.87M$22.11M(m)$15.89M
2025-03-31(m)$14.67M$22.99M(m)-$17.71M
2024-09-30(m)$11.40M$17.96M(m)-$24.18M
2024-06-30(m)$12.66M$19.69M(m)$13.84M
2024-03-31$5.84M$9.74M$19.19M(m)-$56.82M
2023-09-30$6.55M$13.00M$19.62M(m)-$9.00M
2023-06-30$5.25M$17.78M$23.89M(m)-$11.39M
2023-03-31$5.94M$18.62M$24.32M(m)-$21.66M
2022-09-30$20.71M$16.54M$22.31M-$321.00K-$7.89M
2022-06-30$39.27M$19.18M$25.41M(m)$8.60M
2022-03-31$34.00M$17.69M$23.23M(m)$28.78M
2021-09-30$24.43M$20.95M$26.40M$15.83M-$17.89M
2021-06-30$19.66M$14.46M$19.21M(m)$4.57M
2021-03-31$11.05M$13.00M$18.21M(m)-$24.60M
2020-09-30$4.65M$13.96M$18.38M$0.00-$9.73M
2020-06-30$0.00$10.73M$16.37M(m)-$24.08M
2020-03-31$0.00$14.72M$18.82M(m)-$19.62M
2019-12-31$6.65M(m)$19.22M(m)-$14.89M
2019-09-30$0.00$8.10M$11.79M(m)-$11.99M
2019-06-30$13.00K$12.13M$16.25M(m)-$16.39M
2019-03-31$10.00K$7.35M$11.87M(m)-$12.07M
2018-12-31$903.00K(m)$15.40M(m)-$14.65M
2018-09-30$0.00$11.88M$15.94M(m)-$16.00M
2018-06-30$0.00$14.41M$18.77M(m)-$18.80M
2018-03-31$0.00$11.14M$15.81M(m)-$15.89M
2017-12-31$17.00K(m)$19.29M(m)-$19.54M
2017-09-30$27.00K$9.50M$13.88M(m)-$14.68M
2017-06-30$26.00K$10.99M$15.90M(m)-$15.97M
2017-03-31$137.00K$11.04M$14.92M(m)-$15.13M
2016-12-31$2.93M(m)$16.79M(m)-$14.08M
2016-09-30$1.05M$6.02M$8.52M(m)-$7.73M
2016-06-30$2.02M$6.00M$8.42M(m)-$6.92M
2016-03-31$2.09M$6.65M$9.03M(m)-$7.48M
2015-12-31$2.13M(m)$9.24M(m)-$6.85M
2015-09-30$1.61M$5.48M$7.68M(m)-$5.72M
2015-06-30$1.24M$5.31M$7.55M(m)-$6.87M
2015-03-31$1.03M(m)$6.84M(m)-$5.73M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$39.89M$55.73M-$23.41M
2025-06-30(m)$29.54M$45.10M-$1.82M
2024-06-30(m)$22.40M$38.88M-$42.99M
2023-06-30$11.19M$36.41M$48.21M-$33.05M
2022-06-30$73.27M$36.87M$48.64M$37.38M
2021-06-30$30.71M$27.47M$37.42M-$20.03M
2020-06-30$0.00$25.45M$35.19M-$43.70M
2019-06-30$23.00K$19.49M$28.11M-$28.47M
2018-06-30$0.00$25.55M$34.58M-$34.68M
2017-06-30$163.00K$22.04M$30.82M-$31.10M
2016-06-30$4.11M$12.65M$17.45M-$14.40M
2015-06-30$2.27M$10.29M$14.40M-$12.60M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$43.34M$66.62M(m)-$37.73M
2024-09-30(m)$33.80M$56.84M(m)-$67.17M
2023-09-30$17.74M$49.41M$67.82M(m)-$42.05M
2022-09-30$93.98M$53.41M$70.95M-$321.00K$29.49M
2021-09-30$55.14M$48.42M$63.81M$15.83M-$37.93M
2020-09-30$4.65M$39.41M$53.57M$0.00-$53.43M
2019-09-30$23.00K$27.59M$39.91M(m)-$40.46M
2018-09-30$0.00$37.43M$50.52M(m)-$50.69M
2017-09-30$190.00K$31.54M$44.70M(m)-$45.78M
2016-09-30$5.15M$18.67M$25.96M(m)-$22.13M
2015-09-30$3.88M$15.77M$22.07M(m)-$18.32M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$58.03M$146.20M-$9.19M-$130.30M
2024-12-31(m)$45.10M$82.81M$287.00K-$77.42M
2023-12-31$26.00M$71.26M$112.42M-$19.00M-$219.71M
2022-12-31$110.78M$72.38M$96.24M-$609.00K$35.38M
2021-12-31$85.08M$68.74M$89.67M$15.97M-$25.69M
2020-12-31$16.60M$54.51M$73.42M$0.00-$68.88M
2019-12-31$6.68M$42.74M$59.13M$0.00-$55.35M
2018-12-31$903.00K$47.69M$65.92M(m)-$65.34M
2017-12-31$207.00K$45.16M$63.99M(m)-$65.32M
2016-12-31$8.08M$29.70M$42.75M(m)-$36.21M
2015-12-31$6.01M$22.98M$31.32M(m)-$25.17M
2014-12-31$3.04M$10.49M$18.44M(m)-$12.88M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23